These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure. Berger R; Moertl D; Huelsmann M; Bojic A; Ahmadi R; Heissenberger I; Pacher R Eur J Heart Fail; 2007 Feb; 9(2):202-8. PubMed ID: 16859992 [TBL] [Abstract][Full Text] [Related]
10. Effects of levosimendan on right ventricular function in patients with advanced heart failure. Parissis JT; Paraskevaidis I; Bistola V; Farmakis D; Panou F; Kourea K; Nikolaou M; Filippatos G; Kremastinos D Am J Cardiol; 2006 Dec; 98(11):1489-92. PubMed ID: 17126656 [TBL] [Abstract][Full Text] [Related]
11. Levosimendan and plasma BNP levels: do inflammatory cytokines regulate BNP in chronic decompensated heart failure? McLachlan CS; Mossop P Eur J Heart Fail; 2006 Mar; 8(2):216-7; author reply 218. PubMed ID: 16488367 [No Abstract] [Full Text] [Related]
12. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. Lilleberg J; Laine M; Palkama T; Kivikko M; Pohjanjousi P; Kupari M Eur J Heart Fail; 2007 Jan; 9(1):75-82. PubMed ID: 16829185 [TBL] [Abstract][Full Text] [Related]
13. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Parissis JT; Adamopoulos S; Antoniades C; Kostakis G; Rigas A; Kyrzopoulos S; Iliodromitis E; Kremastinos D Am J Cardiol; 2004 May; 93(10):1309-12. PubMed ID: 15135713 [TBL] [Abstract][Full Text] [Related]
14. A struggle to SURVIVE: to abandon or not to abandon levosimendan? Butler J; Giamouzis G; Giannakoulas G Cardiovasc Drugs Ther; 2007 Oct; 21(5):401-2. PubMed ID: 17701453 [No Abstract] [Full Text] [Related]
15. Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients. Kyrzopoulos S; Adamopoulos S; Parissis JT; Rassias J; Kostakis G; Iliodromitis E; Degiannis D; Kremastinos DT Int J Cardiol; 2005 Mar; 99(3):409-13. PubMed ID: 15771921 [TBL] [Abstract][Full Text] [Related]
16. [Levosimendan--an alternative to conventional inotropic treatment of patients with acute heart failure?]. Rasmussen T; Schmidt H Ugeskr Laeger; 2006 Jan; 168(3):261-5. PubMed ID: 16430807 [TBL] [Abstract][Full Text] [Related]
17. Levosimendan: a review of its use in the management of acute decompensated heart failure. Innes CA; Wagstaff AJ Drugs; 2003; 63(23):2651-71. PubMed ID: 14636085 [TBL] [Abstract][Full Text] [Related]
18. Effects of levosimendan on markers of kidney function in patients with acutely decompensated heart failure and renal impairment. Rafouli-Stergiou P; Parissis JT; Farmakis D; Bistola V; Frogoudaki A; Vasiliadis K; Ikonomidis I; Paraskevaidis I; Kremastinos D; Filippatos G; Lekakis J J Cardiovasc Med (Hagerstown); 2017 Oct; 18(10):771-773. PubMed ID: 25643197 [No Abstract] [Full Text] [Related]
19. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers. Bergh CH; Andersson B; Dahlström U; Forfang K; Kivikko M; Sarapohja T; Ullman B; Wikström G Eur J Heart Fail; 2010 Apr; 12(4):404-10. PubMed ID: 20335355 [TBL] [Abstract][Full Text] [Related]
20. Medical support and surgery of the failing heart: levosimendan. Toller W; Knez I Scand J Surg; 2007; 96(2):121-4. PubMed ID: 17679353 [No Abstract] [Full Text] [Related] [Next] [New Search]